Lineage-specific reprogramming as a strategy for cell therapy

Radbod Darabi, Rita C R Perlingeiro

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Embryonic stem (ES) cells are endowed with extensive ability for self renewal and differentiation. These features make them a promising candidate for cell therapy. However, despite the enthusiasm and hype surrounding the potential therapeutic use of human ES cells and more recently induced pluripotent stem (iPS) cells, to date few reports have documented successful therapeutic outcome with ES-derived cell populations. This is probably due to two main caveats associated with ES cells, their capacity to form teratomas and the challenge of isolating the appropriate therapeutic cell population from differentiating ES cells. We have focused our efforts on the derivation of skeletal muscle progenitors from ES cells and here we will discuss the strategy of reprogramming lineage choices by overexpression of a master regulator, which has proven successful for the generation of the skeletal myogenic lineage from mouse ES cells.

Original languageEnglish (US)
Pages (from-to)1732-1737
Number of pages6
JournalCell Cycle
Issue number12
StatePublished - Jun 15 2008


  • Cell therapy
  • ES cells
  • Lineage reprogramming
  • Muscular dystrophy
  • Myogenesis
  • Pax3
  • Regeneration


Dive into the research topics of 'Lineage-specific reprogramming as a strategy for cell therapy'. Together they form a unique fingerprint.

Cite this